This Is Why with Dr. Busti

This Is Why exists to help medical professionals understand the why behind the decisions they make every day in patient care. Our approach is about integrating evidence, clinical relevance and real-world application so that what your learn connects directly with the patients you serve.

This Is Why with Dr. Busti is a education podcast hosted by Dr. Busti, with 115 episodes on record and a Required Pod Score of 80.

Dr. Busti hosts This Is Why with Dr. Busti, a education show with 115 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  This Is Why with Dr. Busti

  How a Systematic Review & Meta-Analysis is Done: Key Steps Explained

  Oct 2, 202646 min

  Systematic reviews and meta-analyses are often considered among the highest levels of clinical evidence—but only when they are performed using rigorous, transparent methods. In this episode of This Is Why with Dr. Busti, you'll learn the essential steps involved in conducting and critically evaluating a systematic review and meta-analysis, from developing a focused clinical question through assessing risk of bias, heterogeneity, and pooled results. Whether you're conducting research or interpreting published medical literature, understanding the systematic review process can help you evaluate the validity of its conclusions. Dr. Busti explains why each step matters and how understanding the methodology supports evidence-based clinical decision making. Topics Covered: - Systematic review and meta-analysis methodology - PICO and PICOTS frameworks - Inclusion and exclusion criteria - Comprehensive literature search strategies - Risk of bias assessment - Cochrane Reviews - Evidence synthesis and pooled estimates - Fixed-effect vs random-effects models - Heterogeneity, Cochran's Q, and I² - Critical appraisal of medical literature If you found this episode valuable, subscribe for more evidence-based clinical education from This Is Why with Dr. Busti, where we explain the why so you can master the how. Access bonus materials and downloads from this episode at: https://www.thisiswhy.health/topics/how-to-do-systematic-review-meta-analysis-ebm-key-steps Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources Chapter Table of Contents 00:00 - Introduction 04:22 - Key Steps in a Systematic Review & Meta-Analysis 08:31 - Defining the Question, Eligibility Criteria & Search Strategy 12:20 - Assessing Study Quality & Risk of Bias 16:29 - How Meta-Analysis Data Are Combined 24:38 - Effect Measures & Fixed vs. Random-Effects Models 31:12 - Choosing the Statistical Method: M-H, Peto & Inverse Variance 35:28 - Forest Plots, Pooled Estimates & Heterogeneity 42:48 - Core Concepts If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #SystematicReview #MetaAnalysis #CriticalAppraisal #EvidenceBasedMedicine #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

  ListenShow Notes
• 

  This Is Why with Dr. Busti

  Systematic Review vs Meta-Analysis: What's the Difference?

  Sep 29, 202624 min

  Systematic Review vs Meta-Analysis is one of the most commonly misunderstood topics in evidence-based medicine. In this episode of This Is Why, Dr. Busti explains the important differences between review articles, systematic reviews, and meta-analyses, why these terms should not be used interchangeably, and how each contributes to clinical decision-making. #SystematicReview #MetaAnalysis #EvidenceBasedMedicine You'll learn why systematic reviews provide a reproducible, evidence-based synthesis of the literature while meta-analyses statistically combine results to estimate an overall treatment effect. Dr. Busti also discusses Cochrane Reviews, publication bias, heterogeneity, the strengths and limitations of evidence synthesis, and a classic cardiovascular example showing how pooled evidence can reveal a treatment signal before a single large trial settles the question. Whether you're a student, resident, pharmacist, physician, nurse practitioner, physician assistant, or practicing clinician, understanding how to interpret systematic reviews and meta-analyses is an essential evidence-based medicine skill. In this episode you'll learn: - What distinguishes a review article from a systematic review - Why systematic reviews follow reproducible methodologies - How meta-analyses produce pooled estimates of treatment effect - Why Cochrane Reviews are widely regarded as among the most rigorous evidence syntheses - Common sources of bias in evidence synthesis - Advantages and limitations of meta-analysis - How systematic reviews and meta-analyses can influence clinical practice Get more with a free membership at https://www.thisiswhy.health/ - Access free downloads from our videos - Access deep dive content from Dr. Busti - Organize content via playlists & collections - Join live Q&A - Receive member newsletters - Coupons & discounts for exam prep resources Chapter Table of Contents 00:00 - Introduction 01:15 - Module Overview and Learning Objectives 02:52 - What Is a Systematic Review? 04:59 - What Is a Meta-Analysis? 06:52 - Systematic Review vs. Traditional Review Article 09:19 - Systematic Reviews, Meta-Analyses, & Cochrane Reviews 14:24 - Benefits and Limitations of Meta-Analysis 18:58 - Can Meta-Analysis Change Clinical Practice? 20:41 - Core Concepts If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #SystematicReview #MetaAnalysis #EvidenceBasedMedicine #CriticalAppraisal #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

  ListenShow Notes
• 

  This Is Why with Dr. Busti

  PARADIGM-HF Trial: Why Sacubitril/Valsartan Changed HFrEF Care

  Sep 24, 202626 min

  Dr. Busti explains why the PARADIGM-HF trial changed treatment for heart failure with reduced ejection fraction (HFrEF), connecting sacubitril/valsartan to the clinical evidence behind angiotensin receptor-neprilysin inhibitor (ARNI) therapy. Why replace an ACE inhibitor in a patient who seems stable? Follow the rationale for neprilysin inhibition, the role of natriuretic peptides, and the reason sacubitril is paired with valsartan. Then examine the comparison with enalapril: cardiovascular death or first heart-failure hospitalization, relative versus absolute benefit, symptomatic hypotension, and the run-in period that shaped trial eligibility. This Landmark Clinical Trials episode also puts PIONEER-HF, PROVE-HF, PARAGON-HF, and PARADISE-MI into perspective without treating biomarker changes or remodeling associations as proof of a survival mechanism. The discussion connects AHA/ACC/HFSA guidance to practical heart failure treatment, including ARNI within the four foundational drug classes, switching precautions, dosing and monitoring, and interpretation of BNP versus NT-proBNP. Designed for healthcare learners and practicing clinicians across medicine, nursing, and pharmacy, this lecture explains what the trial established, why the treatment strategy made sense, and where its findings should not be generalized. When we understand the why, we improve the how. Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep-dive content from Dr. Busti Organize content via playlists & collections Join live Q&A Receive member newsletters Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #PARADIGMHF #SacubitrilValsartan #HFrEF #ARNI #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines aligned with the principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

  ListenShow Notes
• 

  This Is Why with Dr. Busti

  TMP-SMX + Spironolactone Drug Interaction: Why Potassium Can Rise

  Sep 22, 202617 min

  Trimethoprim-sulfamethoxazole, or TMP-SMX, and spironolactone can impair renal potassium excretion through different mechanisms. This lecture explains how trimethoprim’s amiloride-like inhibition of ENaC converges with mineralocorticoid-receptor antagonism—and why that can increase the risk of clinically important hyperkalemia. Dr. Busti will explain how normal distal-nephron potassium handling works, which patients are most vulnerable, how to interpret the observational safety signal, and how clinicians can approach indication review, renal dosing, laboratory monitoring, medication reconciliation, and patient counseling. Evidence discussed: - Antoniou T, et al. BMJ. 2011;343:d5228. https://pubmed.ncbi.nlm.nih.gov/21911446/ - Antoniou T, et al. CMAJ. 2015;187(4):E138-E143. https://pubmed.ncbi.nlm.nih.gov/25646289/ - Spironolactone prescribing information: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4239da9e-dd0c-9af0-e063-6394a90a3cbb - Sulfamethoxazole/trimethoprim prescribing information: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b89b5502-ce87-45a6-a43c-9891da3cfca4 When we understand the why, we improve the how. Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep-dive content from Dr. Busti Organize content via playlists & collections Join live Q&A Receive member newsletters Coupons & discounts for exam prep resources If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this channel continue producing free, high-yield medical education content. Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #DrugInteractions #Hyperkalemia #Spironolactone #TMPSMX #DrBusti Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines aligned with the principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

  ListenShow Notes
• 

  This Is Why with Dr. Busti

  Amiodarone and Digoxin: Drug Interaction Explained

  Jul 7, 202613 min

  The amiodarone and digoxin drug interaction is one of the most clinically important cardiovascular drug interactions to understand because it can raise digoxin exposure and increase the risk of digoxin toxicity. In this episode of This Is Why, Dr. Busti explains why amiodarone can increase digoxin concentrations, how P-glycoprotein inhibition changes digoxin handling, and why clinicians should anticipate the need for digoxin dose adjustment and monitoring rather than react after symptoms appear. You’ll learn why this interaction is not just a memorized warning, but a predictable pharmacokinetic and pharmacodynamic issue involving drug transport, renal elimination, cardiac conduction, and patient-specific monitoring. Topics Covered: Why digoxin has a narrow therapeutic window How P-glycoprotein affects digoxin absorption and elimination Why amiodarone increases digoxin exposure Clinical signs of digoxin toxicity Why nausea, fatigue, confusion, and bradycardia matter How to think through dose reduction and monitoring Why renal function and serum concentrations matter Additive electrophysiologic effects on heart rate and conduction How understanding the mechanism improves patient care When we understand the why, we improve the how. 👉 Get more with a free membership at https://www.thisiswhy.health/ Access free downloads from our videos Access deep-dive content from Dr. Busti Organize content via playlists & collections Join live Q&A Receive member newsletters Coupons & discounts for exam prep resources Chapter Table of Contents 00:00 - Introduction 01:49 - Digoxin's Narrow Therapeutic Index 02:31 - P-Glycoprotein: The Key Transporter 04:53 - How Amiodarone Inhibits P-Glycoprotein 06:37 - Clinical Signs of Digoxin Toxicity 08:27 - Managing the Interaction 09:59 - Pharmacodynamic Effects on Cardiac Conduction 11:19 - Key Clinical Takeaways 👍 If this helped you, please like, subscribe, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content. 🔔 Don’t forget to turn on notifications so you don’t miss upcoming lectures in pharmacology, medical rounds, and more! #Amiodarone #Digoxin #DrugInteraction #DigoxinToxicity #PGlycoprotein Speaker: Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, is a licensed healthcare professional and medical educator with over 30 years of experience in clinical practice and academic teaching. He has trained and practiced as a nurse, pharmacist, and physician, bringing a uniquely comprehensive perspective to patient care and medical education. Dr. Busti is dedicated to advancing evidence-based medicine and helping clinicians understand the underlying “why” behind clinical decisions to improve patient outcomes. About This Channel: This content is created by Anthony Busti, MD, PharmD, MSc, FAHA, FNLA, a board-certified physician with training at Johns Hopkins School of Medicine and University of Oxford and a medical educator for healthcare professionals and students. All material is based on current medical literature and evidence-based guidelines that align with principles of evidence-based medicine (EBM) and Evidence-Based Healthcare (EBHC). Disclaimer: This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.

  ListenShow Notes

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.